Newron Pharmaceuticals S.p.A.
NWRN.SWDrugs in Pipeline
10
Phase 3 Programs
5
Upcoming Catalysts
1
Next Catalyst
Next quarter
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Safinamide (as add-on therapy)
Idiopathic Parkinson's Disease
Safinimide 50-100 mg/day
Idiopathic Parkinson's Disease
Evenamide 15 mg bid
Treatment-resistant Schizophrenia
Ralfinamide
Pain
Safinamide
Idiopathic Parkinson's Disease
Evenamide
Schizophrenia
Safinamide + Levodopa
Idiopathic Parkinson's Disease
NW-3509A
Chronic Schizophrenia
sNN0029
Amyotrophic Lateral Sclerosis
sNN0031
Parkinson's Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Safinamide (as add-on therapy) | Phase 3 | Idiopathic Parkinson's Disease | - | - |
Safinimide 50-100 mg/day | Phase 3 | Idiopathic Parkinson's Disease | - | - |
Evenamide 15 mg bid | Phase 3 | Treatment-resistant Schizophrenia | - | - |
Ralfinamide | Phase 3 | Pain | - | - |
Safinamide | Phase 3 | Idiopathic Parkinson's Disease | - | - |
Evenamide | Phase 2 | Schizophrenia | - | - |
Safinamide + Levodopa | Phase 2 | Idiopathic Parkinson's Disease | - | - |
NW-3509A | Phase 2 | Chronic Schizophrenia | - | - |
sNN0029 | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
sNN0031 | Phase 2 | Parkinson's Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Newron Pharmaceuticals S.p.A.'s drug pipeline?→
CatalystAlert tracks 10 drug candidates in Newron Pharmaceuticals S.p.A.'s (NWRN.SW) pipeline across Phase 3, Phase 2. Its lead program is Safinamide (as add-on therapy) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Newron Pharmaceuticals S.p.A.'s next FDA catalyst?→
Newron Pharmaceuticals S.p.A.'s (NWRN.SW) next tracked catalyst is a Phase 3 expected December 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NWRN.SW biotech catalysts?→
Add NWRN.SW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Newron Pharmaceuticals S.p.A.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.